Equity (Details) - USD ($) |
12 Months Ended | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 12, 2026 |
Nov. 07, 2025 |
Oct. 22, 2025 |
Oct. 20, 2025 |
Oct. 15, 2025 |
Aug. 23, 2025 |
Jan. 24, 2025 |
Dec. 13, 2023 |
Nov. 15, 2023 |
Dec. 14, 2021 |
Feb. 09, 2021 |
Feb. 06, 2021 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|||
| Equity [Line Items] | ||||||||||||||||
| Aggregate net proceeds (in Dollars) | $ 2,100,000 | $ 1,141,000 | ||||||||||||||
| Common stock, shares issued | [1] | 520,964 | 300,249 | |||||||||||||
| Reverse stock split | 1:14-reverse-split | |||||||||||||||
| 2021 Warrants [Member] | ||||||||||||||||
| Equity [Line Items] | ||||||||||||||||
| Aggregate shares of common stock | 3,228,807 | 3,655,000 | 1,998,500 | |||||||||||||
| Price per share (in Dollars per share) | $ 7.8 | $ 6.805 | ||||||||||||||
| Aggregate net proceeds (in Dollars) | $ 10,525,819 | $ 26,100,000 | $ 12,400,000 | |||||||||||||
| Aggregate shares | 1,998,500 | |||||||||||||||
| Warrants price per share (in Dollars per share) | $ 4 | $ 7.8 | $ 6.805 | |||||||||||||
| Warrants term | 5 years 6 months | 5 years 6 months | ||||||||||||||
| Purchase of warrants | 4,843,210 | 3,655,000 | ||||||||||||||
| Purchase price for common stock and warrants (in Dollars per share) | $ 3.26 | |||||||||||||||
| Warrants to purchase of common stock | 4,843,210 | |||||||||||||||
| Issuance of consultant shares | 500,000 | |||||||||||||||
| Closing bid price of common stock (in Dollars) | $ 150,000,000 | |||||||||||||||
| 2025 Warrants [Member] | ||||||||||||||||
| Equity [Line Items] | ||||||||||||||||
| Aggregate shares of common stock | 3,000,000 | 1,141,000 | ||||||||||||||
| Price per share (in Dollars per share) | $ 0.7 | $ 1.63 | ||||||||||||||
| Aggregate net proceeds (in Dollars) | $ 2,100,000 | |||||||||||||||
| Aggregate shares | 700,000 | 1,700,000 | ||||||||||||||
| Warrants price per share (in Dollars per share) | $ 6.07 | $ 6.07 | ||||||||||||||
| Warrants to purchase of common stock | 1 | |||||||||||||||
| Warrants exercisable | 1,700,000 | |||||||||||||||
| Aggregate price of private placement (in Dollars) | $ 9,860,000 | |||||||||||||||
| Common stock, shares issued | 1,700,000 | |||||||||||||||
| Subsequently returned funds (in Dollars) | $ 9,860,000 | |||||||||||||||
| Warrants issuable | 1,700,000 | 1,700,000 | ||||||||||||||
| Reverse stock split | 121,429 warrants after reverse stock split of 14 shares to 1 | 214,286 shares after reverse stock split of 14 shares to 1 | 50,000 shares after reverse stock split of 14 shares to 1 | |||||||||||||
| Exercise price reverse stock split | 84.98 after reverse stock split of 14 shares to 1 | |||||||||||||||
| 2025 Warrants [Member] | Zhikang Huang [Member] | ||||||||||||||||
| Equity [Line Items] | ||||||||||||||||
| Cash paid for settlement (in Dollars) | $ 300,000 | |||||||||||||||
| Shares issued | 90,000 | 90,000 | ||||||||||||||
| Reverse stock split | 6,429 shares after reverse stock split of 14 shares to 1 | |||||||||||||||
| Common Stock [Member] | ||||||||||||||||
| Equity [Line Items] | ||||||||||||||||
| Reverse stock split | On July 27, 2026, the Company effected a one-for-fourteen (1-for-14) reverse stock split of its outstanding common stock and amended and restated the number of share of common stock which the Company shall have authority to issue shall be 50 billion shares, without par value per share. All share and per-share amounts, including basic and diluted net income (loss) per share, have been retrospectively adjusted for all periods presented to reflect the reverse stock split. The reverse stock split did not affect the Company’s net loss or shareholders’ equity. | |||||||||||||||
| ||||||||||||||||
| X | ||||||||||
- Definition It represents closing bid price of common stock. No definition available.
|
| X | ||||||||||
- Definition Description of exercise price stock split. No definition available.
|
| X | ||||||||||
- Definition Purchase price for each share of common stock. No definition available.
|
| X | ||||||||||
- Definition Subsequently returned funds. No definition available.
|
| X | ||||||||||
- Definition Warrants issuable. No definition available.
|
| X | ||||||||||
- Definition Warrants to purchase of common stock. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of cash paid for the settlement of litigation or for other legal issues during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash inflow from the additional capital contribution to the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. No definition available.
|
| X | ||||||||||
- Definition Price of a single share of a number of saleable stocks of a company. No definition available.
|
| X | ||||||||||
- Definition Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Number of shares of stock issued attributable to transactions classified as other. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|